Assyro AI

Purple Book product · Reference 351(a)

Eloctate

Antihemophilic Factor (Recombinant), Fc Fusion protein

351(a)BLA 125487RxLicensed Bioverativ Therapeutics, Inc.

Jun 06, 2014

Approved

Reference 351(a)

License type

Rx

Marketing

None

Listed patents

Eloctate (Antihemophilic Factor (Recombinant), Fc Fusion protein) is Bioverativ Therapeutics, Inc.'s FDA-licensed reference biologic, approved under a 351(a) BLA in 2014. No biosimilars referencing Eloctate are listed in the Purple Book yet.

Sourced from the FDA Purple Book · verified Jul 02, 2026

Key dates

  1. Approval

    Approval date of this BLA submission.

    Jun 06, 2014

    12 yr 4 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    Jun 06, 2021

    5 yr 2 mo ago

  3. Today

Pharmaceutical detail

Strength

1000IU

Dosage form

For Injection

Route

Intravenous

Presentation

Single-Dose Vial

Center

CBER

License number

2078

Product number

002

Submission type

Original

Supplement number

0

Change type

Not listed

Reference product family

View full family

This is the reference (originator) product. No biosimilars or interchangeables reference it in the Purple Book yet.

9 additional BLA records for this product (other strengths or presentations) are in the same reference family.

Patent list

No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.

Source provenance

Source kind · Advanced Search
Checked Jul 02, 2026
  • advanced-searchAdvanced Search · Jul 02, 2026
  • monthly-downloadMonthly download · Jul 02, 2026

Change history

  • v4Jul 02, 2026
  • v3Jul 02, 2026
  • v2Jul 02, 2026

Frequently asked questions

Does Eloctate have approved biosimilars?

No 351(k) biosimilars or interchangeable biosimilars referencing Eloctate are listed in the FDA Purple Book yet.

What is Eloctate's BLA number?

Eloctate is licensed under BLA 125487, held by Bioverativ Therapeutics, Inc..

When was Eloctate approved by the FDA?

Eloctate was approved by the FDA on Jun 06, 2014.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.